The present invention relates to a method of mono-deuterated-lower-alkylating the amine part in a compound having an amine protected with an aralkyl, which comprises introducing mono-deuterated lower-alkyl into the amine with a deuterated-lower-alkylating agent under neutral or basic condition, and then deprotecting the aralkyl group.

Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.

The present invention relates to a novel cathode buffer layer material and an organic photoelectric device including the same. When the novel compound of the present invention is applied to a cathode buffer layer of an organic photoelectric device, for example, an organic solar cell or an organic photodiode, there is an effect in which the surface characteristics of an electron transport layer are improved through the high dipole moment of the novel compound to thereby facilitate electron extraction from a photoactive layer to a cathode electrode and to reduce series resistance and leakage current, and accordingly, the performance of an organic optoelectronic device (organic solar cell, organic photodiode, etc.) to be manufactured can be remarkably improved, which is industrially advantageous.

The present invention relates to a novel cathode buffer layer material and an organic photoelectric device including the same. When the novel compound of the present invention is applied to a cathode buffer layer of an organic photoelectric device, for example, an organic solar cell or an organic photodiode, there is an effect in which the surface characteristics of an electron transport layer are improved through the high dipole moment of the novel compound to thereby facilitate electron extraction from a photoactive layer to a cathode electrode and to reduce series resistance and leakage current, and accordingly, the performance of an organic optoelectronic device (organic solar cell, organic photodiode, etc.) to be manufactured can be remarkably improved, which is industrially advantageous.

Fluorescent compounds that have aggregation-induced emission (AIE) characteristics. The compounds can be utilized as lipid droplet (LD)-specific bio-probes in cell imaging, with high photostability and brightness. For example, the compounds can be used for specific two-photon LDs staining in live cells and deep-tissues at ultralow concentrations. The compounds exhibit a large Stokes shift (>110 nm), high solid fluorescence quantum yields (up to 0.30), a good two-photon absorption cross-section (45-100 GM at 860 nm), high biocompatibility, and good photostability.

Fluorescent compounds that have aggregation-induced emission (AIE) characteristics. The compounds can be utilized as lipid droplet (LD)-specific bio-probes in cell imaging, with high photostability and brightness. For example, the compounds can be used for specific two-photon LDs staining in live cells and deep-tissues at ultralow concentrations. The compounds exhibit a large Stokes shift (>110 nm), high solid fluorescence quantum yields (up to 0.30), a good two-photon absorption cross-section (45-100 GM at 860 nm), high biocompatibility, and good photostability.

The present invention relates to a compound of the following formula (I): ##STR00001## The invention also relates to uses thereof as dye or pigment, notably as a luster pigment. The invention relates also to a reflective or photonic or nanophotonic or optoelectronic device comprising a compound of the invention. The invention relates also to a metal-like reflective coating, a metal-like particle or an organic-based metal-like liquid film comprising a compound of the invention.

The present application discloses stilbene derivative compounds and compositions, and methods for treating ocular diseases, neurological disorders and protein aggregation-related disorders in patients using the compounds and compositions as disclosed herein.

The present application discloses stilbene derivative compounds and compositions, and methods for treating ocular diseases, neurological disorders and protein aggregation-related disorders in patients using the compounds and compositions as disclosed herein.

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.